Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4636143
Max Phase: Preclinical
Molecular Formula: C40H44N12O4
Molecular Weight: 756.87
Molecule Type: Unknown
Associated Items:
ID: ALA4636143
Max Phase: Preclinical
Molecular Formula: C40H44N12O4
Molecular Weight: 756.87
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1cc(C[C@@H](NC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)C(=O)N[C@@H](Cc2ccncc2)C(=O)N2CCN(c3ccncc3)CC2)cc2cn[nH]c12
Standard InChI: InChI=1S/C40H44N12O4/c1-26-21-28(22-29-25-44-48-35(26)29)24-32(46-39(55)51-15-8-31(9-16-51)52-34-3-2-10-43-36(34)47-40(52)56)37(53)45-33(23-27-4-11-41-12-5-27)38(54)50-19-17-49(18-20-50)30-6-13-42-14-7-30/h2-7,10-14,21-22,25,31-33H,8-9,15-20,23-24H2,1H3,(H,44,48)(H,45,53)(H,46,55)(H,43,47,56)/t32-,33+/m1/s1
Standard InChI Key: OIPRTBOJXKHIGX-SAIUNTKASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 756.87 | Molecular Weight (Monoisotopic): 756.3608 | AlogP: 2.73 | #Rotatable Bonds: 10 |
Polar Surface Area: 190.13 | Molecular Species: BASE | HBA: 10 | HBD: 4 |
#RO5 Violations: 1 | HBA (Lipinski): 16 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 10.67 | CX Basic pKa: 8.69 | CX LogP: 1.21 | CX LogD: 0.48 |
Aromatic Rings: 6 | Heavy Atoms: 56 | QED Weighted: 0.16 | Np Likeness Score: -1.18 |
1. Bucknell SJ, Ator MA, Brown AJH, Brown J, Cansfield AD, Cansfield JE, Christopher JA, Congreve M, Cseke G, Deflorian F, Jones CR, Mason JS, O'Brien MA, Ott GR, Pickworth M, Southall SM.. (2020) Structure-Based Drug Discovery of N-((R)-3-(7-Methyl-1H-indazol-5-yl)-1-oxo-1-(((S)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine., 63 (14): [PMID:32558564] [10.1021/acs.jmedchem.0c01003] |
Source(1):